NASDAQ:MRKR

Marker Therapeutics Q4 2024 Earnings Results & Report

Marker Therapeutics logo
$0.85 +0.02 (+1.98%)
Closing price 04:00 PM Eastern
Extended Trading
$0.85 +0.00 (+0.09%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Marker Therapeutics missed analyst expectations on both earnings and revenue in its Q4 2024 results, released March 31, 2025. The company reported EPS of -$0.42 versus the -$0.28 consensus estimate, while revenue of $1.22 million fell short of the $5.25 million estimate by $4.03 million.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Marker Therapeutics EPS Results

Actual EPS
-$0.42
Consensus EPS
-$0.28
Beat/Miss
Missed by -$0.14
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Marker Therapeutics Revenue Results

Actual Revenue
$1.22 million
Expected Revenue
$5.25 million
Beat/Miss
Missed by -$4.03 million
YoY Revenue Growth
N/A

Marker Therapeutics Q4 2024 Earnings FAQ

Marker Therapeutics (NASDAQ:MRKR) reported earnings of -$0.42 per share for Q4 2024, missing the consensus estimate of -$0.28. The report was announced on Monday, March 31, 2025.

Marker Therapeutics reported revenue of $1.22 million for Q4 2024, against a consensus estimate of $5.25 million.

Marker Therapeutics Earnings Headlines

Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
See More Marker Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Marker Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Marker Therapeutics and other key companies, straight to your email.

About Marker Therapeutics

Marker Therapeutics is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. Its platform aims to produce T cells that recognize multiple tumor-associated antigens, with the goal of helping them target cancer cells while reducing the risk that tumors evade treatment by losing a single antigen.

The company’s pipeline includes multi-antigen-specific T-cell candidates for blood cancers. Its programs have included MT-601, studied for lymphoma, and MT-401, developed for acute myeloid leukemia and other hematologic malignancies. These candidates are investigational and remain in clinical development.

Marker Therapeutics was formed in 2018 through a merger involving TapImmune and Marker Therapeutics (NASDAQ:MRKR); TapImmune subsequently adopted the Marker Therapeutics name. The company is based in Houston, Texas, and its development work centers on advancing cell-based cancer treatments.

View Marker Therapeutics Profile